Analysis of patients who have already received Chemo & radiation for esophageal & gastroesophageal junction cancer
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Esophageal & Gastroesophageal cancer patients who have already received chemoradiation
- Registration Number
- CTRI/2014/07/004776
- Lead Sponsor
- ot Applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
We will include all patients who have received chemotherapy at Tata Memorial Hospital concurrently with radical radiotherapy for esophageal and GE junction carcinoma, from January 2011 onwards (to date), whose data has been prospectively entered in a database that has been maintained in the medical oncology department at Tata Memorial Hospital.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary objective:- <br/ ><br>To assess the toxicity of weekly Carboplatin and Paclitaxel in combination with radical radiotherapy in patients with esophageal and GE junction cancer. <br/ ><br>Timepoint: Acute toxicity weekly while on CTRT <br/ ><br>Then at 6 weeks after completion of CTRT <br/ ><br>Then every 3 months for first 2 years and <br/ ><br>At any point in between as needed.
- Secondary Outcome Measures
Name Time Method Secondary objectives:- <br/ ><br>1.Overall survival <br/ ><br>2.Progression-free survival <br/ ><br>3.Response rate <br/ ><br>4.Evaluate factors that affect toxicity. <br/ ><br>5.Evaluate factors that affect survival. <br/ ><br>Timepoint: Yes we will assess mortality at 1 year , 3 years